Why the study?
In patients with kidney impairment, long-term troponin elevations are common and challenging to interpret, leaving the effect of implementing hs-cTn testing on diagnosis and clinical outcomes uncertain.
Does implementing hs-cTn testing improve the diagnosis and outcomes of patients with kidney impairment?
Does implementing hs-cTn testing improve the diagnosis and outcomes of patients with kidney impairment?
The effect of implementing high-sensitivity cardiac troponin testing on the diagnosis and outcomes of patients with kidney impairment remains uncertain.
Answers are grounded in this paper and cite their sources.
Uncertainty in hs-cTn effects for kidney impairment warrants diagnostic caution; leaves open need for dedicated outcome trials.
High-sensitivity cardiac troponin (hs-cTn) assays have improved the diagnosis of myocardial infarction in patients with healthy kidney function and are now widely used in clinical practice. 1 However, in patients with kidney impairment, long-term elevations in troponin levels are common, and interpretation can be more challenging. 2 As such, the effect of implementing hs-cTn testing on the diagnosis and outcomes of patients with kidney impairment is uncertain.
No takes yet. Share an insight, caveat, or question.
Gallacher et al. (2021) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: